Piper Jaffray reiterates Overweight rating on Apyx after Q4 revenue beat

Piper Jaffray analyst Matt O’Brien reiterated an Overweight rating on Apyx Medical, formerly Bovie Medical, after the company reported preliminary Q4 revenues for continuing operations of $5.9M-$6.1M, better than the consensus estimate of $5.2M. O’Brien sees the “refocused salesforce firing on all cylinders” and a number of encouraging catalysts expected in 2019, including dermal resurfacing indication, and international and salesforce expansion, and encourages risk tolerant investors to look at this “rapidly growing technology leader.”
https://thefly.com/landingPageNews.php?id=2845029